| | DECEMBER 20258CIOReviewAI AND PHARMA INDUSTRY By Dr. Alejandro P. Bagliano, LATAM South Medical Affairs Head, BiogenIN MY OPINIONYou may have heard or read about artificial intelligence (AI) and other terms like big data, data mining, and machine learning, increasing over the past years. No matter in which industry you are or what type of job you have, these technologies will reshape daily tasks whether you are working at home or office based. We live at the beginning of a revolution, and it would be wise to consider what is coming.The health system and the pharmaceutical industry are no strangers to this phenomenon. The inclusion of AI in these areas has already started. Currently, a continuous acceleration is perceived, but what is sure, they will impact significantly in the next 5 to 10 years.If you look at the number of works published on health scientific databases like PUBMED, you can see that the amount has been increasing steadily since 2000 but has accelerated in the last five years. (Graphic N°1).This trend comprises works focusing on a broad specter of topics ranging from molecule analysis to disease diagnosis or monitoring. Also, this behavior can be seen if you search for specific diseases like AI and Alzheimer's disease. (Graphic 2).Something that helped AI make this jump in the last years is the fantastic amount of data accumulated that is available and continues to increase at a spectacular speed as we speak. Data Data mining, machine learning techniques, and other AI-related branches and applications allow us to compare, correlate or match biological data obtained from an individual and contrast it to large cohorts databases.Dr. Alejandro P. Bagliano
< Page 7 | Page 9 >